- Rare disease-focused Apellis Pharmaceuticals Inc (NASDAQ:APLS) is reportedly drawing takeover interest from large drugmakers.
- The company is in talks with advisers to consider its options amid the interest, Bloomberg reported citing people familiar with the matter.
- Apellis may also consider seeking partnerships or licensing agreements for some of its ophthalmology products, the report added. Deliberations are ongoing, and there’s no certainty they will lead to a transaction.
- In February, the FDA approved Apellis’ Syfovre (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), making it the first and only FDA-approved treatment for GA.
- Analyst estimates forecast peak revenue of more than $1 billion.
- Getting together with another pharmaceutical company would give Apellis access to more resources and infrastructure to market and distribute Syfovre to U.S. patients.
- In 2021, the FDA approved Apellis Pharma’s Empaveli (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria, a rare blood disorder.
- The company commands a market cap of almost $7.3 billion at the time of publication, according to Benzinga Pro.
- In 2022, Empaveli generated sales of $65.1 million, with an overall sales of $75.4 million for Apellis.
- As of December 31, 2022, Apellis had $551.8 million in cash and cash equivalents.
- Price Action: APLS shares are up 16.90% at $77.14 on the last check Monday.
“Widespread Delays After UK Airspace Hit By ‘Network-Wide Failure’; National Air Traffic Services Says The Problem Has Been ‘rectified’ But There Is Still A Huge Backlog Of Flights” – Evening Standard
https://www.standard.co.uk/news/uk/uk-airspace-loganair-failure-airports-planes-flights-b1103302.html?utm_medium=Social&utm_source=Twitter#Echobox=1693233278
There are widespread delays at several airports after UK
